Can biotech startups survive a downturn? Is Covid-19 a good business? And when did ophthalmology get so dramatic?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss how some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.
For more on what we cover, here’s the news on Celsius Therapeutics; here’s more on EQRx; here’s the latest on Apellis Pharmaceuticals; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.
Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].